Clinical trials: Chemoradiotherapy
HEAD AND NECK CANCER
Accelerated Fractionation Radiotherapy (AFRT) Versus Concurrent Chemoradiotherapy (Crt) In Locally Advanced Head And Neck Squamous Cell Carcinoma
The aim of this trial is to compare the accelerated fractionation radiotherapy and concurrent chemo-radiotherapy in locally advanced head and neck squamous cell carcinoma patients in terms of loco-regional control, toxicities and…
- Trial name
- NCT01291095
- Testing
- CISPLATIN, EXTERNAL BEAM RADIOTHERAPY
- Where
- India
- Volunteers
- 80 people
- Sponsor
- All India Institute of Medical Sciences
Rectal Cancer
Longterm Functional Outcomes in Patients Undergoing Organ Preserving Treatment for Rectal Cancer With or Without Local Excision After Chemoradiotherapy
Treatment of rectal cancer by standard neoadjuvant chemoradiotherapy protocols leads to a complete response in about 15% of patients, or even a higher fraction if radiotherapy is followed by an Oxaliplatin based chemotherapy as…
- Trial name
- PRESERVE (NCT06249672)
- Testing
- Local excision
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Esophageal Cancer
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy such as paclitaxel, fluorouracil, and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00069953
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- 97 sites in United States
- Volunteers
- 43 people
- Sponsor
- Radiation Therapy Oncology Group
Rectal Cancer
A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer
The combination of short course radiotherapy and immunotherapy helps to increase the proportion of pathological complete response after neoadjuvant therapy, providing more patients with the opportunity for organ preservation.
- Trial name
- NCT06608537
- Testing
- neoadjuvant SCRT followed by Sintilimab plus CAPOX
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Neoadjuvant Chemotherapy and Low-dose Radiotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma（NPC）is common malignant tumor in China. The incidence of NPC in most parts of the world and the country is less than 1/10 million, but the incidence rate in China's Guangdong, Guangxi, Fujian and other…
- Trial name
- NCT05292027
- Testing
- low-dose radiotherapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Cervical Cancer, Adjuvant Chemotherapy
A Trial Comparing Adjuvant Chemotherapy With Observation After Concurrent Chemoradiotherapy of Cervical Cancer (With Pelvic or Para-aortic Node Involvement)
Cervical cancer with pelvic or para-aortic node involvement has a poor prognosis. Despite low-quality data, the routine practice to treat these patients is radiation with concurrent cisplatin.
- Conditions
- Cervical Cancer, Adjuvant Chemotherapy, Radiation, Lymph Node Metastases
- Trial name
- NCT03468010
- Testing
- chemoradiation, Paclitaxel, Cisplatin
- Where
- 8 sites in China
- Volunteers
- 432 people
- Sponsor
- Sun Yat-sen University
Rectal Adenocarcinoma
Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy
Treatment for locally-advanced rectal adenocarcinoma includes preoperative radiochemotherapy before surgery with total mesorectal excision in order to reduce tumor infiltration, facilitate oncologic surgery and improve survival.
- Trial name
- PROTEORECTUM (NCT00855946)
- Where
- France
- Volunteers
- 46 people
- Sponsor
- University Hospital, Bordeaux
Nasopharyngeal Neoplasms
PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
This trial is aimed to investigate whether adjuvant PD-1 antibody treatment could improve survival in locoregionally advanced nasopharyngeal carcinoma compared to best supportive care.
- Trial name
- DIPPER (NCT03427827)
- Testing
- Camrelizumab
- Where
- 11 sites in China
- Volunteers
- 450 people
- Sponsor
- Sun Yat-sen University
Head and Neck Neoplasms
Docetaxel in Head and Neck Cancer
Primary Objective: Phase II: To determine the best treatment scheme (TPF vs. PF). Phase III: To compare the time to progression and the treatment failure at the 3 arms. Secondary objectives: To evaluate the safety at the 3 arms.
- Trial name
- NCT00261703
- Testing
- Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy, Cisplatin, 5-fluorouracil (5-FU), radiotherapy, Cisplatin + radiotherapy
- Where
- 2 sites in Portugal, Spain
- Volunteers
- 439 people
- Sponsor
- Sanofi
Lung Cancer, Carcinoma, Non-Small Cell Lung
Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab
This study is designed to determine if combining consolidative radiation therapy (RT) using a hypofractionated regimen (hfRT) (2 fractions) for boosting the residual primary lung cancer with adjuvant anti-PD-L1 therapy…
- Trial name
- NCT04748419
- Testing
- consolidative hypofractionated radiation therapy (hfRT), Durvalumab 50 MG/ML
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Nebraska
Head and Neck Cancer
Fluorouracil, Cisplatin, and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Nasopharyngeal Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00093665
- Testing
- cisplatin, fluorouracil, radiation therapy
- Where
- 7 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Aichi Cancer Center
Head and Neck Cancer
Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving erlotinib after chemoradiotherapy may kill more tumor cells.
- Trial name
- NCT00079053
- Testing
- erlotinib hydrochloride, adjuvant therapy
- Where
- 2 sites in Canada
- Volunteers
- 19 people
- Sponsor
- NCIC Clinical Trials Group
Locally Advanced Gastric Cancer
Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
To evaluate the efficacy and safety of chemoradiotherapy combined with tirelizumab in the treatment of initial unresectable locally advanced gastric cancer or gastroesophageal junction cancer.
- Trial name
- NCT05528367
- Testing
- Nab-PTX,S-1,Tirelizumab, Chemoradiation
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Zhejiang Cancer Hospital
Neoadjuvant Therapy in Rectal Cancer
Preoperative Radiotherapy and E7046 in Rectum Cancer
This is a multicenter, open-label, Phase 1b study in participants with locally advanced rectum cancer where primary resection without chemoradiotherapy is unlikely to achieve clear margins as defined by magnetic resonance imaging…
- Trial name
- PRAER 1 (NCT03152370)
- Testing
- E7046, Long Course Chemoradiotherapy (LCRT), Short Course Radiotherapy (SCRT)
- Where
- 5 sites in United States, Poland and 1 more
- Volunteers
- 29 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Pancreatic Cancer
Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
This study is being conducted to find out what effects (good and bad) that a combination of treatment with chemotherapy, radiation therapy and surgery has on you and your pancreatic cancer.
- Trial name
- NCT00761241
- Testing
- Gemcitabine, Docetaxel, 5FU, Oxaliplatin, Alpha-interferon, Abdominal/pelvic radiation therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Benaroya Research Institute
Locally Advanced Cervical Cancer
A Clinical Study of Pelvic Concurrent Chemoradiotherapy Combined with CT-guided Intracavitary Brachytherapy with Adaptive Simultaneous Dose Escalation for Locally Advanced Cervical Cancer
The standard treatment for locally advanced cervical cancer is cisplatin-based concurrent chemoradiotherapy with external beam radiotherapy (EBRT) and Brachytherapy (BT).
- Trial name
- NCT06882473
- Testing
- Brachytherapy and CT-guided online adaptive external beam pelvic radiotherapy are delivered on the same day
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Third Hospital
Esophageal Carcinoma, Limited-Stage Small Cell Esophageal Carcinoma
The Impact of Surgical Treatment on Survival in Localized Small Cell Esophageal Cancer
Limited-stage small cell esophageal carcinoma (LS-SCEC) is a rare and highly aggressive malignancy with poor prognosis and no established standard treatment strategy.
- Trial name
- NCT07596654
- Where
- China
- Volunteers
- 4 people
- Sponsor
- yi shen
Human Papilloma Virus, HPV
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
Doctors leading this study hope to learn about the safety and effectiveness of combining medications HB-201 and HB-202 (also known as TheraT® vectors) with chemotherapy using carboplatin and paclitaxel in the beginning of the…
- Conditions
- Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT05108870
- Testing
- HB-201, HB-202, Carboplatin
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Chicago
Anal Cancer
Role of Antisecretory Factor in Curative Radiochemotherapy for Anal Carcinoma
Curative radiochemotherapy (RCT) for anal carcinoma (AC) is associated with considerable acute and long-term toxicity. The acute toxicity derives from the combined effects of radiation and chemotherapy and is dominated by…
- Trial name
- SALFLAC (NCT05351931)
- Volunteers
- 38 people
- Sponsor
- Uppsala University Hospital
Head Cancer, Neck Cancer
Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study
The aim of the AURACCO study is to evaluate the association between the onset of tinnitus and hearing loss in patients with locally advanced head and neck cancer treated by concomitant chemoradiotherapy or exclusive radiotherapy
- Trial name
- AURACCO (NCT05946577)
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.